Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Subscribe To Our Newsletter & Stay Updated
